Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

Eduard Dolušić; Pierre Larrieu; Sébastien Blanc; Frédéric Sapunaric; Bernadette Norberg; Laurence Moineaux; Delphine Colette; Vincent Stroobant; Luc Pilotte; Didier Colau; Thierry Ferain; Graeme Fraser; Moreno Galeni; Jean Marie Frre; Bernard Masereel; Benoît Van Den Eynde; Johan Wouters; Raphaël Frédérick

doi:10.1016/j.bmc.2010.12.032

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

Eduard Dolušić, Pierre Larrieu, Sébastien Blanc, Frédéric Sapunaric, Bernadette Norberg, Laurence Moineaux, Delphine Colette, Vincent Stroobant, Luc Pilotte, Didier Colau, Thierry Ferain, Graeme Fraser, Moreno Galeni, Jean Marie Frre, Bernard Masereel, Benoît Van Den Eynde, Johan Wouters, Raphaël Frédérick

Research output: Contribution to journal › Article › peer-review

619 Downloads (Pure)

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a heme dioxygenase which has been shown to be involved in the pathological immune escape of diseases such as cancer. The synthesis and structure-activity relationships (SAR) of a novel series of IDO inhibitors based on the indol-2-yl ethanone scaffold is described. In vitro and in vivo biological activities have been evaluated, leading to compounds with IC ₅₀ values in the micromolar range in both tests. Introduction of small substituents in the 5- and 6-positions of the indole ring, indole N-methylation and variations of the aromatic side chain are all well tolerated. An iron coordinating group on the linker is a prerequisite for biological activity, thus corroborating the virtual screening results. © 2011 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1550-1561
Number of pages	12
Journal	Bioorganic & medicinal chemistry
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/j.bmc.2010.12.032
Publication status	Published - 15 Feb 2011
Event	JFB 2011. - Liege, Belgium Duration: 19 May 2011 → …

Keywords

Anticancer
IDO
Immunotherapy
Indoleamine 2,3-dioxygenase

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bmc.2010.12.032

BMC 8927 corrSubmitted manuscript, 2.07 MB

Cite this

Dolušić, E., Larrieu, P., Blanc, S., Sapunaric, F., Norberg, B., Moineaux, L., Colette, D., Stroobant, V., Pilotte, L., Colau, D., Ferain, T., Fraser, G., Galeni, M., Frre, J. M., Masereel, B., Van Den Eynde, B., Wouters, J., & Frédérick, R. (2011). Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. Bioorganic & medicinal chemistry, 19(4), 1550-1561. https://doi.org/10.1016/j.bmc.2010.12.032

@article{549ce448cb964da7a8d40fdc0f746cb2,

title = "Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors",

abstract = "Indoleamine 2,3-dioxygenase (IDO) is a heme dioxygenase which has been shown to be involved in the pathological immune escape of diseases such as cancer. The synthesis and structure-activity relationships (SAR) of a novel series of IDO inhibitors based on the indol-2-yl ethanone scaffold is described. In vitro and in vivo biological activities have been evaluated, leading to compounds with IC 50 values in the micromolar range in both tests. Introduction of small substituents in the 5- and 6-positions of the indole ring, indole N-methylation and variations of the aromatic side chain are all well tolerated. An iron coordinating group on the linker is a prerequisite for biological activity, thus corroborating the virtual screening results. {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",

keywords = "Anticancer, IDO, Immunotherapy, Indoleamine 2,3-dioxygenase",

author = "Eduard Dolu{\v s}i{\'c} and Pierre Larrieu and S{\'e}bastien Blanc and Fr{\'e}d{\'e}ric Sapunaric and Bernadette Norberg and Laurence Moineaux and Delphine Colette and Vincent Stroobant and Luc Pilotte and Didier Colau and Thierry Ferain and Graeme Fraser and Moreno Galeni and Frre, {Jean Marie} and Bernard Masereel and {Van Den Eynde}, Beno{\^i}t and Johan Wouters and Rapha{\"e}l Fr{\'e}d{\'e}rick",

year = "2011",

month = feb,

day = "15",

doi = "10.1016/j.bmc.2010.12.032",

language = "English",

volume = "19",

pages = "1550--1561",

journal = "Bioorganic & medicinal chemistry",

issn = "0968-0896",

publisher = "Elsevier",

number = "4",

note = "JFB 2011. ; Conference date: 19-05-2011",

}

Dolušić, E, Larrieu, P, Blanc, S, Sapunaric, F, Norberg, B , Moineaux, L, Colette, D, Stroobant, V, Pilotte, L, Colau, D, Ferain, T, Fraser, G, Galeni, M, Frre, JM, Masereel, B, Van Den Eynde, B, Wouters, J & Frédérick, R 2011, 'Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors', Bioorganic & medicinal chemistry, vol. 19, no. 4, pp. 1550-1561. https://doi.org/10.1016/j.bmc.2010.12.032

TY - JOUR

T1 - Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

AU - Dolušić, Eduard

AU - Larrieu, Pierre

AU - Blanc, Sébastien

AU - Sapunaric, Frédéric

AU - Norberg, Bernadette

AU - Moineaux, Laurence

AU - Colette, Delphine

AU - Stroobant, Vincent

AU - Pilotte, Luc

AU - Colau, Didier

AU - Ferain, Thierry

AU - Fraser, Graeme

AU - Galeni, Moreno

AU - Frre, Jean Marie

AU - Masereel, Bernard

AU - Van Den Eynde, Benoît

AU - Wouters, Johan

AU - Frédérick, Raphaël

PY - 2011/2/15

Y1 - 2011/2/15

N2 - Indoleamine 2,3-dioxygenase (IDO) is a heme dioxygenase which has been shown to be involved in the pathological immune escape of diseases such as cancer. The synthesis and structure-activity relationships (SAR) of a novel series of IDO inhibitors based on the indol-2-yl ethanone scaffold is described. In vitro and in vivo biological activities have been evaluated, leading to compounds with IC 50 values in the micromolar range in both tests. Introduction of small substituents in the 5- and 6-positions of the indole ring, indole N-methylation and variations of the aromatic side chain are all well tolerated. An iron coordinating group on the linker is a prerequisite for biological activity, thus corroborating the virtual screening results. © 2011 Elsevier Ltd. All rights reserved.

AB - Indoleamine 2,3-dioxygenase (IDO) is a heme dioxygenase which has been shown to be involved in the pathological immune escape of diseases such as cancer. The synthesis and structure-activity relationships (SAR) of a novel series of IDO inhibitors based on the indol-2-yl ethanone scaffold is described. In vitro and in vivo biological activities have been evaluated, leading to compounds with IC 50 values in the micromolar range in both tests. Introduction of small substituents in the 5- and 6-positions of the indole ring, indole N-methylation and variations of the aromatic side chain are all well tolerated. An iron coordinating group on the linker is a prerequisite for biological activity, thus corroborating the virtual screening results. © 2011 Elsevier Ltd. All rights reserved.

KW - Anticancer

KW - IDO

KW - Immunotherapy

KW - Indoleamine 2,3-dioxygenase

UR - http://www.scopus.com/inward/record.url?scp=79951555163&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2010.12.032

DO - 10.1016/j.bmc.2010.12.032

M3 - Article

C2 - 21269836

SN - 0968-0896

VL - 19

SP - 1550

EP - 1561

JO - Bioorganic & medicinal chemistry

JF - Bioorganic & medicinal chemistry

IS - 4

T2 - JFB 2011.

Y2 - 19 May 2011

ER -

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)

Indoleamine 2,3-Dioxygenase Inhibitory Activity of Derivatives of Marine Alkaloid Tsitsikammamine A

Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

CANTOL: Design and synthesis of indolamine dioxygenase (IDO) for the treatment of cancer

Physical Chemistry and characterization(PC2)

47th RICT: Drug Discovery and Selection.

JFB 2011.

XVIIIeme JOURNEE JEUNES CHERCHEURS

CCDC 794451: Experimental Crystal Structure Determination

CCDC 794450: Experimental Crystal Structure Determination

Cite this

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Research output

Projects

Equipment

Activities

Datasets

Cite this